With the International Monetary Fund (IMF) and the World Bank cutting South Africa’s economic growth forecast for 2016 to 0.7% and 0.8% respectively, if economic objectives are not met the country faces the risk of its sovereign credit rating being downgraded to junk status. As the manufacturers and distributers of medication and contributors to the national economy, the leading pharmaceutical companies have a key role to play in the seemingly turbulent year ahead.
This is according to Paul Miller, CEO of Cipla Medpro – the third largest pharmaceutical manufacturer in South Africa, who says that “top business leaders must work in partnership and with a common purpose with the State in each sector in their quest to further economic growth in the country. Significant foreign investment and job creation are key elements for businesses to focus on this year if we are going to grow the economy.”
He explains that Cipla will continue to support the local economy through continued foreign investment. “As a testament of Cipla’s commitment to improve healthcare in South Africa, Cipla Global invested 4.5-billion into the country as one of the biggest foreign direct investments into South Africa in 2013. In addition, a total of R400-million was invested into our local manufacturing facility.”
Miller adds that as big players in the economy, the leading pharmaceutical organisations have a responsibility to contribute to economic growth, but must not lose sight of their primary responsibility to ensure access to affordable healthcare for consumers. “The latest price increase approved for pharmaceuticals is 4.8%, but we hope that government would support an extra price increase later this year to cushion the pharmaceutical companies against the sharp slide in the rand, which has made imports more expensive.”
In light of this it is essential for pharmaceutical manufacturers to invest and focus on their local manufacturing facilities in order to boost the production of local medication, he explains. “Over the past few years, R400-million was invested into Cipla’s local manufacturing facility. The net effect was an increase in capacity from 20% to 100% with the main focus on HIV products.
Miller explains that “Cipla hopes to assist in growing the economy further by continuing to invest in the manufacturing and distribution of medication. Another solution that will enable greater access to required medication for patients, is if the Medical Control Council approval process can be expedited.”
He also points to the importance of generic competition to drive the costs of medication down in the country. “In the generics market, prices typically don’t go up, they only come down and so greater investment into the development and distribution of generics and biosimilars will increase competition and will ultimately provide greater access to quality medicines at affordable prices.”
“In these tough times, it is vital for all of us to pull together as a nation and to work in collaboration with Government in achieving its economic milestones for 2016. As a leading pharmaceutical manufacturer we often focus on advancing healthcare for all, but as an organisation Cipla also invests in advancing the economic wellbeing of all South Africans.
In the interest of our patients, in accordance with South African law and our commitment to expertise, MediHub cannot subscribe to the practice of online diagnosis. Please consult a medical professional for specific medical advice. If you have any major concerns, please see your doctor for an assessment. If you have any cause for concern, your GP will be able to direct you to the appropriate specialists.